S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
International Paper's 5% Yield Offers Big Value
Would Buffett Approve of This Growth Strategy? (Ad)
Warren Buffett's company dumps another 5 million shares of printer maker HP
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Would Buffett Approve of This Growth Strategy? (Ad)
Stock market today: World shares are mostly lower, tracking a rates-driven tumble on Wall Street
Inflation is Why a Soft Landing is Bad for the Economy
Would Buffett Approve of This Growth Strategy? (Ad)
EU announces plans to better protect its sensitive technologies from foreign snooping
A Growing 4% Dividend makes this a REIT to Shop For
NYSE:TARO

Taro Pharmaceutical Industries (TARO) Stock Forecast, Price & News

$37.18
-0.14 (-0.38%)
(As of 10/3/2023 ET)
Compare
Today's Range
$36.79
▼
$37.36
50-Day Range
$35.49
▼
$40.13
52-Week Range
$22.89
▼
$42.22
Volume
20,699 shs
Average Volume
24,020 shs
Market Capitalization
$1.40 billion
P/E Ratio
65.23
Dividend Yield
N/A
Price Target
$35.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Taro Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
5.9% Downside
$35.00 Price Target
Short Interest
Healthy
3.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.26mentions of Taro Pharmaceutical Industries in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars

Medical Sector

850th out of 966 stocks

Pharmaceutical Preparations Industry

391st out of 440 stocks

See Top Rated MarketRank™ Stocks Here

TARO stock logo

About Taro Pharmaceutical Industries (NYSE:TARO) Stock

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

TARO Price History

TARO Stock News Headlines

September 29, 2023 | americanbankingnews.com
StockNews.com Upgrades Taro Pharmaceutical Industries (NYSE:TARO) to "Strong-Buy"
September 28, 2023 | msn.com
Proactiv Parent Company Cuts Jobs
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
September 27, 2023 | ca.finance.yahoo.com
Sun Pharma Canada Launches (PR)WINLEVI® (clascoterone cream 1% w/w), a Novel Topical Treatment for Acne
September 24, 2023 | americanbankingnews.com
Taro Pharmaceutical Industries (NYSE:TARO) Stock Price Down 2.5%
August 16, 2023 | seekingalpha.com
Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)
July 31, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Taro Pharmaceutical (TARO), Boston Scientific (BSX)
July 27, 2023 | finance.yahoo.com
Taro Provides Results for the Quarter Ended June 30, 2023
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
July 19, 2023 | finance.yahoo.com
Krensavage Asset Management Opposes Sun's Lowball Bid for Taro
July 8, 2023 | theglobeandmail.com
Instrument Name Taro Pharm Inds Instrument Symbol (TARO-N)
June 30, 2023 | finance.yahoo.com
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2023
June 2, 2023 | seekingalpha.com
Taro Pharmaceutical: Potential Value In Sun Pharma Offer
June 2, 2023 | msn.com
Sun Pharma's Latest Cash Offer for Taro Might Actually Seal the Deal This Time Around
May 30, 2023 | finance.yahoo.com
Why Shares of Taro Pharmaceutical Are Rising Tuesday
May 30, 2023 | msn.com
HeartBeam, Taro top healthcare gainers; Enveric, Bright Health among losers
May 30, 2023 | marketwatch.com
Taro Pharmaceutical Shares Surge Premarket as Sun Pharma Proposes Buyout >TARO
May 27, 2023 | seekingalpha.com
Taro Pharma weighing offer from Sun Pharma to acquire company at $38 share
May 24, 2023 | msn.com
Taro Pharmaceutical misses top an bottom line consensus for Q1
May 23, 2023 | finance.yahoo.com
Taro Provides Results for Year Ended March 31, 2023
May 23, 2023 | markets.businessinsider.com
What Wall Street expects from Taro Pharmaceutical Industries's earnings
May 16, 2023 | marketwatch.com
2023 to 2030, Hydrocortisone Butyrate Market: Business Strategic and Growth Analysis
May 12, 2023 | marketwatch.com
Nystatin and Triamcinolone Acetonide Market 2023 to Hit Statistical Significance Value by 2030
May 10, 2023 | marketwatch.com
Future of Clindamycin Phosphate Topical Market 2023: Active Key Players and Emerging Trends in Industry till 2030
May 10, 2023 | marketwatch.com
Lice Treatment Market Qualitative and Quantitative Inputs Drive Industry Growth
May 8, 2023 | marketwatch.com
The Takotsubo Syndrome Therapeutics Market Trends: 2023 Segmentation in Customer Targeting
May 3, 2023 | marketwatch.com
Enalapril Market 2023 : Recent Developments, Industry Trends and Investigation Growth Rate, and Forecast to 2031
See More Headlines
Receive TARO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taro Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TARO Company Calendar

Last Earnings
7/26/2023
Today
10/03/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
3/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:TARO
CUSIP
N/A
CIK
906338
Web
www.taro.com
Phone
(724) 847-5700
Fax
914-345-6169
Employees
1,554
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
-5.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.57
Trailing P/E Ratio
65.23
Forward P/E Ratio
38.73
P/E Growth
N/A
Net Income
$25.44 million
Net Margins
3.72%
Pretax Margin
4.80%
Return on Equity
1.52%
Return on Assets
1.24%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.36
Quick Ratio
2.83

Sales & Book Value

Annual Sales
$572.95 million
Price / Sales
2.44
Cash Flow
$1.72 per share
Price / Cash Flow
21.56
Book Value
$46.05 per share
Price / Book
0.81

Miscellaneous

Outstanding Shares
37,580,000
Free Float
32,398,000
Market Cap
$1.40 billion
Optionable
Optionable
Beta
0.60
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Uday V. Baldota (Age 53)
    CEO & Director
  • Mr. William J. Coote (Age 68)
    VP, CFO & Chief Accounting Officer
  • Mr. Itamar Karsenti (Age 51)
    VP & Head of Operations
  • Mr. Avi Avramoff (Age 58)
    VP and Head of R&D
  • Mr. Itzik Baruch (Age 60)
    VP of Technical Services
  • Dr. Roman Kaplan (Age 76)
    VP of Scientific and Technical Compliance Mang.
  • Mr. Erik Zwicker J.D. (Age 43)
    VP, Gen. Counsel & Sec.
  • Mr. Ara Aprahamian (Age 55)
    VP of Sales & Marketing
    Comp: $616.14k
  • Ms. Michele Visosky (Age 57)
    VP & Head of Human Resource
  • Mr. Jayesh Shah (Age 67)
    Head of Procurement

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













TARO Stock - Frequently Asked Questions

Should I buy or sell Taro Pharmaceutical Industries stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TARO shares.
View TARO analyst ratings or view top-rated stocks.

What is Taro Pharmaceutical Industries' stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price targets for Taro Pharmaceutical Industries' stock. Their TARO share price forecasts range from $35.00 to $35.00. On average, they anticipate the company's share price to reach $35.00 in the next year. This suggests that the stock has a possible downside of 5.9%.
View analysts price targets for TARO or view top-rated stocks among Wall Street analysts.

How have TARO shares performed in 2023?

Taro Pharmaceutical Industries' stock was trading at $29.04 at the beginning of the year. Since then, TARO shares have increased by 28.0% and is now trading at $37.18.
View the best growth stocks for 2023 here.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 256,800 shares, a decrease of 35.6% from the August 31st total of 398,600 shares. Based on an average trading volume of 43,400 shares, the short-interest ratio is currently 5.9 days. Approximately 3.2% of the shares of the company are sold short.
View Taro Pharmaceutical Industries' Short Interest.

When is Taro Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our TARO earnings forecast.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) posted its earnings results on Wednesday, July, 26th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.09. The business had revenue of $158.89 million for the quarter, compared to analyst estimates of $149 million. Taro Pharmaceutical Industries had a net margin of 3.72% and a trailing twelve-month return on equity of 1.52%.

What ETF holds Taro Pharmaceutical Industries' stock ?

ARK Israel Innovative Technology ETF holds 58,404 shares of TARO stock, representing 2.19% of its portfolio.

What is Uday Baldota's approval rating as Taro Pharmaceutical Industries' CEO?

11 employees have rated Taro Pharmaceutical Industries Chief Executive Officer Uday Baldota on Glassdoor.com. Uday Baldota has an approval rating of 19% among the company's employees. This puts Uday Baldota in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Bausch Health Companies (BHC), Broadcom (AVGO), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals (GWPH), Delta Air Lines (DAL), Jazz Pharmaceuticals (JAZZ) and Southwest Airlines (LUV).

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $37.18.

How much money does Taro Pharmaceutical Industries make?

Taro Pharmaceutical Industries (NYSE:TARO) has a market capitalization of $1.40 billion and generates $572.95 million in revenue each year. The company earns $25.44 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Taro Pharmaceutical Industries have?

The company employs 1,554 workers across the globe.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The official website for the company is www.taro.com. The company can be reached via phone at (724) 847-5700, via email at investorrelations@taro.com, or via fax at 914-345-6169.

This page (NYSE:TARO) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -